Last month, the World Health Organization updated its guidelines for GLP-1 drugs like Ozempic and Wegovy
References Ast J, Arvaniti A, Fine NHF, Nasteska D, Ashford FB, Stamataki Z, Koszegi Z, Bacon A, Jones BJ, Lucey MA, Sasaki S, Brierley DI, Hastoy B, Tomas A, DAgostino G, Reimann F, Lynn FC, Reissaus CA, Linnemann AK, DEste E, Calebiro D, Trapp S, Johnsson K, Podewin T, Broichhagen J, Hodson DJ
Thats no longer thought to be true
Growth trajectory for the next 3-4 years should be good for a company where on a 3-4 yr basis the company is looking to grow at a 20% CAGR with margins improving as the CMS mix stabilises for the company + scaling up of Peptide business where management is looking to scale it in the similar manner as CMS
Due to its hygroscopic nature, the product may absorb moisture and clump